北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学第二临床医学院  > 血液科  > 期刊论文
学科主题: 临床医学
题名:
Continued Overall Survival Benefit After 5 Years′ Follow-up with Bortezomib-Melphalan-Prednisone (VMP) Versus Melphalan-Prednisone (MP) in Patients with Previously Untreated Multiple Myeloma, and No Increased Risk of Second Primary Malignancies: Final Results of the Phase 3 VISTA Trial
作者: San Miguel, Jesus F.1; Schlag, Rudolf2; Khuageva, Nuriet K.3; Dimopoulos, Meletios Athanasios4; Shpilberg, Ofer5; Kropff, Martin6; Spicka, Ivan7; Petrucci, Maria T.8; Palumbo, Antonio9; Samoilova, Olga S.10; Dmoszynska, Anna11; Abdulkadyrov, Kudrat M.12; Delforge, Michel13; Jiang, Bin14; Mateos, Maria-Victoria1; Anderson, Kenneth C.; Esseltine, Dixie-Lee16; Liu, Kevin17; Deraedt, William M.18; Cakana, Andrew Z.19; van de Velde, Helgi18; Richardson, Paul G.15
刊名: BLOOD
发表日期: 2011-11-18
卷: 118, 期:21, 页:221-222
收录类别: SCI ; ISTP
文章类型: Meeting Abstract
WOS标题词: Science & Technology
类目[WOS]: Hematology
研究领域[WOS]: Hematology
语种: 英语
WOS记录号: WOS:000299597100477
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/56547
Appears in Collections:北京大学第二临床医学院_血液科_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Janssen Res & Dev, High Wycombe, Bucks, England
2.Praxisklin Dr Schlag, Wurzburg, Germany
3.SP Botkin Moscow City Clin Hosp, Moscow, Russia
4.Rabin Med Ctr, Inst Hematol, Petah Tiqwa, Israel
5.Univ Munster, Munster, Germany
6.Charles Univ Prague, Prague, Czech Republic
7.Univ Roma La Sapienza, Rome, Italy
8.Belgian Hematol Soc, Myeloma Study Grp, Brussels, Belgium
9.Janssen Res & Dev, Raritan, NJ USA
10.Janssen Res & Dev, Beerse, Belgium
11.Nizhnii Novgorod Reg Clin Hosp, Novgorod, Russia
12.Med Univ Lublin, Lublin, Poland
13.St Petersburg Clin Res Inst Hematol & Transfusiol, St Petersburg, Russia
14.Hosp Clin Univ, Salamanca, Spain
15.Univ Athens, Sch Med, Dept Clin Therapeut, GR-11527 Athens, Greece
16.Univ Turin, Div Hematol, Myeloma Unit, AOU S Giovanni Battista, Turin, Italy
17.Peking Univ, Peoples Hosp, Inst Hematol, Beijing Key Lab Hematopoiet Stem Cell Transplanta, Beijing 100871, Peoples R China
18.Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
19.Millennium Pharmaceut Inc, Cambridge, MA USA

Recommended Citation:
San Miguel, Jesus F.,Schlag, Rudolf,Khuageva, Nuriet K.,et al. Continued Overall Survival Benefit After 5 Years′ Follow-up with Bortezomib-Melphalan-Prednisone (VMP) Versus Melphalan-Prednisone (MP) in Patients with Previously Untreated Multiple Myeloma, and No Increased Risk of Second Primary Malignancies: Final Results of the Phase 3 VISTA Trial[J]. BLOOD,2011,118(21):221-222.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[San Miguel, Jesus F.]'s Articles
[Schlag, Rudolf]'s Articles
[Khuageva, Nuriet K.]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[San Miguel, Jesus F.]‘s Articles
[Schlag, Rudolf]‘s Articles
[Khuageva, Nuriet K.]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace